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stem cells is the standard by which their plurip-
otent potential is evaluated.1-3 We believe that the 
intended application of human induced pluripo-
tent stem-cell lines should determine the evalua-
tion method. The issue of pluripotency becomes 
important for studies of the functional mecha-
nism of reprogramming. However, a reproduc-
ible and rapid method to determine the quality of 
newly established human pluripotent stem cells 
is urgently required. Perhaps an epigenetic and 
gene-expression signature that selectively defines 
fully reprogrammed pluripotent stem cells can be 
identified, since the variation of teratoma results 
brings up the question of this assay’s value as a 
standard for proving pluripotency of human 
stem cells.4
We tested our lines for the reactivation of en-
dogenous pluripotency genes, the silencing of ret-
roviral transgenes, and the capacity to form the 
three germ layers. In close collaboration with the 
pathology department, we are in the process of 
correlating the results of teratoma assays with the 
ability to generate functional cardiac myocytes. 
Although induced cardiomyocytes may replace 
pluripotent stem cells for disease modeling, this 
technique needs to be reproducibly established in 
human cells.
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Rapid Molecular Detection of Tuberculosis
To the Editor: Boehme et al. (Sept. 9 issue)1 
report encouraging results on the use of an auto-
mated molecular test for Mycobacterium tuberculosis 
and resistance to rifampin (Xpert MTB/RIF). How-
ever, the population of patients with clinical tu-
berculosis who have negative cultures still poses a 
problem of interpretation, which was not dis-
cussed in the article. Among study patients whose 
samples were culture-negative but who had symp-
toms of tuberculosis, 29.3% had positive results 
on the automated test; these patients made up 
4.3% of the total number of automated test–pos-
itive patients.
In such patients, tuberculosis that was detect-
ed by the automated test may have had a false 
negative culture because of low bacillary load or 
overgrowth, but the possibility of false positiv-
ity cannot be excluded. Furthermore, 23 patients 
with nontuberculous mycobacteria in culture were 
excluded from the analysis. In our site in Tanzania 
and in other African locations, nontuberculous 
mycobacteria are frequently found in culture,2,3 
so the capability of the automated test to dis-
criminate between tuberculosis and nontubercu-
lous mycobacteria, for which preliminary results 
have been encouraging,4 would be of great inter-
est. More effort should be made in future studies 
to elaborate on these two groups, thus clearing an 
uncertainty regarding the performance of the 
automated test.
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To the Editor: Although resistance to rifampin 
and isoniazid usually occurs concomitantly, ri-
fampin monoresistance is known and well docu-
mented in certain populations.1-3 When the auto-
mated test detects rifampin resistance, clinicians 
would have to consider further diagnostic and 
treatment options. First, would the strain be as-
sumed to have multidrug resistance, given the 
high probability of concomitant resistance to 
isoniazid? In that event, treatment options would 
probably include the remaining first-line agents 
(ethambutol and pyrazinamide) plus a fluoroquin-
olone and an injectable antituberculosis agent.4 
Clinicians may still prescribe isoniazid until re-
sistance to the drug is excluded. Further testing 
with the use of either a traditional assay or the 
Genotype MTBDRplus assay would still be need-
ed. Nonetheless, at least one or more second-line 
agents would be initiated early in the treatment 
of the strain of tuberculosis with at least partial 
resistance. However, patients with rifampin mono-
resistance may be unnecessarily exposed to the 
untoward effects of injectable agents for tubercu-
losis until the complete drug-susceptibility pat-
tern is obtained. Additional detection of isonia-
zid resistance would substantially enhance the 
utility of this test.
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To the Editor: Boehme et al. report that an au-
tomated test for tuberculosis had a sensitivity of 
97.6% and a specificity of 98.1% for the correct 
identification of patients with rifampin-resistant 
tuberculosis. Even though the test greatly ad-
vances the direct detection of M. tuberculosis, cor-
rect identification of rifampin-sensitive strains is 
essential, since the false diagnosis of multidrug-
resistant tuberculosis is deleterious for patients.1
We have identified a patient with rifampin-
sensitive tuberculosis for whom automated test-
ing of bronchoalveolar lavage falsely showed ri-
fampin resistance. The M. tuberculosis bacterial 
load detected by the automated test was low. The 
curve pattern generated in the automated test re-
sulted in the interpretation “rifampin resistance 
detected.” In contrast, rpoB sequencing,2,3 line-
probe testing (AID Diagnostika), repeated culture, 
and phenotypic drug-susceptibility testing revealed 
the presence of fully susceptible M. tuberculosis. 
In this patient, short-course therapy resulted in 
a clinical response.
A major limitation of the design of the auto-
mated test is that interpretation relies solely on 
a decreased level (or the absence) of wild-type 
beacon hybridization, rather than additional hy-
bridization to mutant probes, which would add 
to the specificity of the test. Our results indicate 
that positive results for rifampin resistance on 
the automated test must be viewed with caution 
and should be confirmed by phenotypic or addi-
tional genotypic methods when possible.
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To the Editor: The study by Boehme et al., 
which reports a high degree of accuracy for an 
automated test for the identification of tubercu-
losis in adults, could revolutionize the diagnosis 
of tuberculosis globally. However, in high-burden 
settings, up to 30% of tuberculosis cases occur 
in children. The diagnosis in this age group is 
challenging, especially in the high-risk groups for 
disease progression and poor outcome, which 
include children who are under the age of 5 years, 
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